Difelikefalin

Drug Profile

Difelikefalin

Alternative Names: CKD-943; CR 845; FE 202845; MR13A9

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Cara Therapeutics; Chong Kun Dang; Maruishi Pharmaceutical
  • Class Opioid analgesics; Peptides
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Postoperative pain; Pruritus
  • Phase II Pain

Most Recent Events

  • 03 Aug 2017 Cara Therapeutics announces intention to submit IND for oral difelikefalin in Chronic liver disease-associated pruritus in the fourth quarter of 2017
  • 03 Aug 2017 Cara Therapeutics plans a phase I trial for oral difelikefalin in Chronic kidney disease-associated pruritus (non-haemodialysis patients) in the fourth quarter of 2017
  • 03 Aug 2017 Cara Therapeutics plans a phase III pivotal trial for Chronic kidney disease-associated pruritus in haemodialysis patients in fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top